FDA Clearance Tracker · P030004-S035
Onyx Liquid Embolic System (LES)
Last checked: Nov 20, 2026Latest source record: Dec 8, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Dec 8, 2025
Approved
Time to decision
419 days
Received Oct 15, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P030004-S035
- Device name
- Onyx Liquid Embolic System (LES)
- Applicant
- Ev3 Neurovascular
- Applicant location
- Irvine, CA
- Received
- Oct 15, 2024
- Decided
- Dec 8, 2025
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P030004
Device type
- Device type
- Neurovascular Liquid Embolic Agent (SGU)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Onyx Liquid Embolic System (LES) is indicated for embolization of the middle meningeal artery (MMA) as an adjunct to surgery for the treatment of symptomatic subacute or chronic subdural hematoma (SDH).
Source documents
Other decisions for Ev3 Neurovascular
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K241388 · Decided Jan 2, 2025 · 232 days after receipt
Device type: Catheter, Percutaneous, Neurovasculature (QJP) · Cardiology
K243418 · Decided Dec 2, 2024 · 28 days after receipt
Device type: Apparatus, Suction, Ward Use, Portable, Ac-Powered (JCX) · General & Plastic Surgery
K243080 · Decided Oct 29, 2024 · 29 days after receipt
Device type: Catheter, Thrombus Retriever (NRY) · Cardiology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.